LEISA BAILEY: Open Payments
NPI 1851314330 · BONIFAY, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$462 in 26 payments from 10 companies in 2025. Trend: 2023 $335 · 2024 $446 · 2025 $462
Food & beverage: $462
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $137 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $63 |
| GlaxoSmithKline, LLC. | 4 | $63 |
| Amgen Inc. | 2 | $36 |
| Novartis Pharmaceuticals Corporation | 2 | $33 |
| ABBVIE INC. | 2 | $33 |
| Indivior Inc. | 1 | $28 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $25 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $24 |
| Novo Nordisk Inc | 1 | $19 |
Products named: AIRSUPRA, CAPLYTA, FARXIGA, TRELEGY ELLIPTA, OTEZLA, LEQVIO, VRAYLAR, SUBLOCADE.
Industry payments across FL — which companies pay providers there.
